Literature DB >> 27677273

Simultaneous Determination of Cytochrome P450 Oxidation Capacity in Humans: A Review on the Phenotyping Cocktail Approach.

Fernando de Andrés, Adrián LLerena1.   

Abstract

Intra- and/or inter-individual variability in drug response is mainly a result of either subtherapeutic or supratherapeutic plasma levels of the active drugs and their metabolites, with this variability mainly being influenced by differences in the rate of drug metabolism. Indeed, drug metabolism is largely determined by genetic polymorphism in the CYP enzymes, which are responsible for approximately 85% of the drug metabolism process. However, this genetic heterogeneity can accurately predict actual drug metabolizing capacity (oxidation phenotype) for some individuals: poor metabolizers (PMs), who cannot produce the drug metabolizing enzymes, and 20% of ultra-rapid metabolizers. According to EMA recommendations, phenotyping procedures for drug interaction studies and clinical research are therefore required to obtain actual data on the main CYP enzymes. With this purpose, cocktail phenotyping approaches give information on the activity of different CYPs in just one experiment. In this review, the issues related to the phenotyping of the main CYP enzymes are reviewed, and the current in vivo phenotyping cocktails are analysed: the sampling procedures, probe drugs utilized, analytical techniques and main applications are also discussed. Based on this analysis, a fully validated cocktail approach to measure the metabolic activity of the main CYP enzymes and drug transporters is still required. This novel approach should fulfil certain conditions: a faster and simpler analytical methodology to obtain information on several CYPs in one experiment, minimal sample amounts, and minimal doses of optimal probe drugs.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 27677273     DOI: 10.2174/1389201017666160926150117

Source DB:  PubMed          Journal:  Curr Pharm Biotechnol        ISSN: 1389-2010            Impact factor:   2.837


  6 in total

1.  Lack of Effect of 12-Week Treatment with Risankizumab on the Pharmacokinetics of Cytochrome P450 Probe Substrates in Patients with Moderate to Severe Chronic Plaque Psoriasis.

Authors:  Amit Khatri; Ling Cheng; Anne Camez; Stanislav Ignatenko; Yinuo Pang; Ahmed A Othman
Journal:  Clin Pharmacokinet       Date:  2019-06       Impact factor: 6.447

2.  Evaluation of phenoconversion phenomenon in obese patients: the effects of bariatric surgery on the CYP450 activity "a protocol for a case-control pharmacokinetic study".

Authors:  Hengameh Ghasim; Mohammadreza Rouini; Kheirollah Gholami; Farnoosh Larti; Saeed Safari; Yalda H Ardakani
Journal:  J Diabetes Metab Disord       Date:  2021-07-31

3.  Effects of Avitinib on CYP450 Enzyme Activity in vitro and in vivo in Rats.

Authors:  Yong Shi; Deru Meng; Shuanghu Wang; Peiwu Geng; Tao Xu; Quan Zhou; Yunfang Zhou; Wanshu Li; Xugao Chen
Journal:  Drug Des Devel Ther       Date:  2021-08-21       Impact factor: 4.162

Review 4.  Ferroptosis and Tumor Drug Resistance: Current Status and Major Challenges.

Authors:  Zhenyu Nie; Mei Chen; Yuanhui Gao; Denggao Huang; Hui Cao; Yanling Peng; Na Guo; Fei Wang; Shufang Zhang
Journal:  Front Pharmacol       Date:  2022-05-20       Impact factor: 5.988

5.  A Strategy to Refine the Phenotyping Approach and Its Implementation to Predict Drug Clearance: A Physiologically Based Pharmacokinetic Simulation Study.

Authors:  Jeffry Adiwidjaja; Alan V Boddy; Andrew J McLachlan
Journal:  CPT Pharmacometrics Syst Pharmacol       Date:  2018-10-24

6.  Effects of Upadacitinib Coadministration on the Pharmacokinetics of Sensitive Cytochrome P450 Probe Substrates: A Study With the Modified Cooperstown 5+1 Cocktail.

Authors:  Mohamed-Eslam F Mohamed; Tian Feng; Jeffrey V Enejosa; Ogert Fisniku; Ahmed A Othman
Journal:  J Clin Pharmacol       Date:  2019-08-05       Impact factor: 3.126

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.